Iterum declares completion of enrollment in sulopenem clinical trial
Category: #health  By Mateen Dalal  Date: 2019-12-27
  • share
  • Twitter
  • Facebook
  • LinkedIn

Iterum declares completion of enrollment in sulopenem clinical trial
  • The clinical trial was aimed at the treatment of uncomplicated urinary tract infections.
  • The enrollment is expected to garner topline results in quarter one of 2020.

Ireland based Iterum Therapeutics has reportedly announced the completion of patient enrollment in its Sulopenem for Resistance Enterobacteriaceae 1, phase 3 clinical trial for uncomplicated urinary tract infections.

For the uninitiated, sulopenem is an innovative penem anti-infective compound with the oral formulations that has exhibited powerful in vitro activity against a vast range of gram negative and positive resistant to the other antibiotics.  

It has been claimed that the clinical trials across 1,670 patients would produce topline results in Q1 2020. Moreover, this multi-center, double-blind trial would measure the efficiency, tolerance, and safety of oral sulopenem for the treatment of uUTI in adult women, and other patients. The patients are randomized to receive either oral sulopenem two times a day for 5 days or are given oral ciprofloxacin twice daily for 3 days.

Speaking on the matter, the CEO of Iterum Therapeutics, Corey Fishman, reportedly quoted that the company is elated to announce the completion of enrollment of its final phase 3 clinical trial for the uUTI with over 1670 patients being treated. Additionally, the trial is expected to produce high quality results in the first quarter of 2020. Mr. Fishman further added that the launch of this new oral treatment fir urinary tract infections is first since a long time period of 20 years. On receiving the safety approval, oral sulopenem would offer an option to all those patients with an elevated risk for treatment failure.

For the records, Iterum Therapeutics is a pharmaceutical company which is focused on making next gen oral and IV antibiotics. Apparently, these antibiotics are used to treat the infections caused by multi-drug anti pathogens in all environments. The company has also received Qualified Infectious Disease Product and Fast Track designations for IV and oral formulations of the sulopenem drug in over seven indications.

Source credit: https://www.iterumtx.com/news/press-releases/detail/30/iterum-therapeutics-announces-completion-of-enrollment-in

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

AstraZeneca to present results of Farxiga’s DAPA-CKD trial at ESC 2020
AstraZeneca to present results of Farxiga’s DAPA-CKD trial at ESC 2020
By Mateen Dalal

According to reliable sources, British-Swedish multinational pharmaceutical company AstraZeneca plc will present the much awaited results of the Phase III DAPA-CKD trial of Farxiga in CKD (chronic kidney disease) at ESC Congress 2020. Sources with r...

FDA grants Emergency Use Authorization to Abbott’s COVID-19 antigen
FDA grants Emergency Use Authorization to Abbott’s COVID-19 antigen
By Mateen Dalal

Abbott Laboratories, a U.S.-based medical devices and healthcare firm, has reportedly received the Emergency Use Authorization (EUA) from the U.S. FDA (Food and Drug Administration) for the detecting COVID-19 virus with its portable antigen test Bina...

Hyundai Wia Corp. signs gun parts export contract with BAE Systems
Hyundai Wia Corp. signs gun parts export contract with BAE Systems
By Mateen Dalal

Hyundai Wia Corp., a South Korea-based defense firm, has reportedly signed gun parts export contract with BAE Systems plc of worth USD 100 million via a pre-value accumulation system. As per the agreement, Hyundai Wia will supply over 106 types of gu...